FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of September 2022
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Board Committee Changes
30 September 2022 10:30 BST
Remuneration Committee Chair Appointment
AstraZeneca PLC today announced the appointment of Sheri McCoy, Non-Executive Director, as Chair of the Remuneration Committee. Sheri has served as a member of the Remuneration Committee since July 2018.
Sheri will succeed Michel Demaré who will step down as Chair of the Remuneration Committee following his recent appointment as Chair-designate of the Board. He will remain a member of the Committee.
Sheri will also become a member of the Nomination and Governance Committee.
These Remuneration Committee and Nomination and Governance Committee changes are effective from 1 December 2022. As previously announced, Michel Demaré will become Chair of the Board at the end of the Company's Annual General Meeting in April 2023.
Notes
Biography and photograph:
https://www.astrazeneca.com/our-company/leadership.html#board
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: 30 September 2022
| | By: /s/ Adrian Kemp |
| | Name: Adrian Kemp |
| | Title: Company Secretary |
